| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S1461145709990654 |
| P698 | PubMed publication ID | 19775502 |
| P50 | author | Surendra P Singh | Q56131568 |
| P2093 | author name string | Kelvin Chan | |
| Vidhi Singh | |||
| P2860 | cites work | Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration | Q21092366 |
| Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics | Q24811190 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia | Q28201028 | ||
| A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia | Q28214489 | ||
| The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial | Q28257509 | ||
| A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia | Q28283422 | ||
| The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia | Q28290520 | ||
| The positive and negative syndrome scale (PANSS) for schizophrenia | Q28301751 | ||
| Role of free radicals and catalytic metal ions in human disease: an overview | Q29618022 | ||
| Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials | Q30934425 | ||
| GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data | Q31170558 | ||
| Integrated approaches towards drug development from Ayurveda and other Indian system of medicines | Q33226652 | ||
| Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation | Q33238062 | ||
| Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics | Q33987036 | ||
| The immune system and schizophrenia. An integrative view. | Q34194859 | ||
| Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications | Q34313506 | ||
| A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group | Q34443696 | ||
| A meta-analysis of the efficacy of second-generation antipsychotics | Q34534321 | ||
| Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials. | Q34542331 | ||
| Interpreting Results and Drawing Conclusions | Q58642721 | ||
| Enzymes of the antioxidant defense system in chronic schizophrenic patients | Q68001335 | ||
| Lipoperoxidation induced by hydrogen peroxide in human erythrocyte membranes. 1. Protective effect of Ginkgo biloba extract (EGb 761) | Q72297170 | ||
| Effectiveness of vitamin E for treatment of long-term tardive dyskinesia | Q72424160 | ||
| Extract of Ginkgo biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia | Q74614503 | ||
| Prevalence of bipolar II disorder in atypical depression | Q77882908 | ||
| T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients | Q78064872 | ||
| Best practices: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital | Q82206423 | ||
| Complementary medicines in psychiatry: review of effectiveness and safety | Q34564616 | ||
| A review of 12 commonly used medicinal herbs | Q34754967 | ||
| The CNS effects of Ginkgo biloba extracts and ginkgolide B. | Q34778214 | ||
| Ginkgo biloba extract neuroprotective action is dependent on heme oxygenase 1 in ischemic reperfusion brain injury. | Q34849985 | ||
| Oxidative mechanisms and tardive dyskinesia | Q35017644 | ||
| Ginkgo biloba for cerebral insufficiency | Q35565662 | ||
| Chinese medicinal materials and their interface with Western medical concepts | Q35978665 | ||
| The negative symptoms of schizophrenia: a cognitive perspective | Q36169573 | ||
| Chinese herbal medicine for schizophrenia: cochrane systematic review of randomised trials. | Q36807291 | ||
| Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis | Q36857579 | ||
| Review: adding Chinese herbal medicine to antipsychotics may improve some outcomes in schizophrenia, but more high quality trials are needed | Q37068478 | ||
| Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem | Q37137008 | ||
| Oxygen radicals and neuropsychiatric illness. Some speculations | Q37152812 | ||
| Polypharmacy with second-generation antipsychotics: a review of evidence | Q37341522 | ||
| Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia | Q39933313 | ||
| Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties | Q40709379 | ||
| Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials | Q40824415 | ||
| Protective effects of Ginkgo biloba against rat liver carcinogenesis | Q42526064 | ||
| Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia | Q43539794 | ||
| Analysis of terpenelactones in Ginkgo biloba by high performance liquid chromatography and evaporative light scattering detection | Q43738679 | ||
| Ginkgo biloba extract-induced relaxation of rat aorta is associated with increase in endothelial intracellular calcium level | Q43780353 | ||
| Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761), in gerbil global brain ischemia | Q43823159 | ||
| Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior | Q43845249 | ||
| Effect of a short- and long-term treatment with Ginkgo biloba extract on amyloid precursor protein levels in a transgenic mouse model relevant to Alzheimer's disease | Q44601052 | ||
| Comparison of antioxidant activity in commercial Ginkgo biloba preparations | Q44663272 | ||
| Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients | Q44680500 | ||
| Reduced fronto-temporal connectivity is associated with frontal gray matter density reduction and neuropsychological deficit in schizophrenia | Q44715735 | ||
| Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism | Q46260468 | ||
| Antioxidant action of Ginkgo biloba extract EGb 761. | Q46441729 | ||
| EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress | Q46458937 | ||
| Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics | Q46821885 | ||
| Association between priapism and concurrent use of risperidone and Ginkgo biloba | Q46972442 | ||
| Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons | Q48188412 | ||
| Ginkgo biloba extract EGb761 reduces the development of amphetamine-induced behavioral sensitization: effects on hippocampal type II corticosteroid receptors | Q48301748 | ||
| The Ginkgo biloba extract, EGb761, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies | Q48415178 | ||
| Effects of over- and under-expression of Cu,Zn-superoxide dismutase on the toxicity of glutamate analogs in transgenic mouse striatum | Q48462406 | ||
| Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia | Q48726753 | ||
| Beta2-microglobulin abnormalities in antipsychotic-naïve schizophrenia: evidence for immune pathogenesis | Q48921017 | ||
| Ginkgo biloba extract EGb 761 attenuates hippocampal neuronal loss and cognitive dysfunction resulting from chronic restraint stress in ovariectomized rats. | Q51737533 | ||
| A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. | Q52026922 | ||
| Relations among clinical scales in schizophrenia. | Q52051079 | ||
| Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. | Q54180800 | ||
| P433 | issue | 2 | |
| P921 | main subject | schizophrenia | Q41112 |
| meta-analysis | Q815382 | ||
| chronic schizophrenia | Q18967121 | ||
| P1104 | number of pages | 15 | |
| P304 | page(s) | 257-271 | |
| P577 | publication date | 2009-09-24 | |
| P1433 | published in | The International Journal of Neuropsychopharmacology | Q7742309 |
| P1476 | title | Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia | |
| P478 | volume | 13 |
| Q37530729 | A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia |
| Q24198987 | Adjunctive antioxidants for bipolar disorder |
| Q36125530 | An overview on adverse drug reactions to traditional Chinese medicines |
| Q24186162 | Antioxidant treatments for schizophrenia |
| Q36736055 | Antioxidants as potential therapeutics for neuropsychiatric disorders |
| Q54574268 | Antipsychotic-like effect of trimetazidine in a rodent model. |
| Q40242750 | Authentication of Ginkgo biloba herbal dietary supplements using DNA barcoding |
| Q36003195 | Cannabis-induced impairment of learning and memory: effect of different nootropic drugs |
| Q54942040 | Effectiveness of Traditional Chinese Medicineas as an Adjunct Therapy for Refractory Schizophrenia: A Systematic Review and Meta Analysis. |
| Q37874626 | Emerging drugs for schizophrenia |
| Q47778933 | Ethnopharmacological approaches in mood and anxiety disorders. The relevance of the oxidative stress status |
| Q47372291 | Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761®. |
| Q94328651 | Ginkgo biloba versus placebo for schizophrenia |
| Q35213673 | How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library |
| Q34301374 | Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis |
| Q28248687 | Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia |
| Q49363880 | Natural Medicines for Psychotic Disorders: A Systematic Review. |
| Q41449646 | Neuroprotection in Schizophrenia and Its Therapeutic Implications |
| Q39552320 | Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. |
| Q37661360 | Oxidative stress and psychological disorders |
| Q24595660 | Oxidative stress in schizophrenia |
| Q34274859 | Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents |
| Q39472796 | Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stress |
| Q39275834 | Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease |
| Q38647035 | Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review |
Search more.